Slough Berkshire, United Kingdom

Rebecca Jayne Wootton


 

 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Rebecca Jayne Wootton

Introduction

Rebecca Jayne Wootton is a notable inventor based in Slough, Berkshire, GB. She has made significant contributions to the field of medicine, particularly in the treatment of autoimmune and inflammatory disorders. Her innovative work has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Rebecca holds a patent for the "Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers." This patent discloses a new, stable trimeric TNFα structure with distorted symmetry. This structure can bind to the TNFR1 receptor, effectively attenuating signaling and providing a potential treatment for diseases associated with the soluble TNFα/TNFR1 interaction. Importantly, the membrane-bound TNFα remains unaffected in its ability to signal through TNFR2, allowing for therapies that do not significantly increase the risk of infection or malignancy. She has 1 patent to her name.

Career Highlights

Throughout her career, Rebecca has worked with prominent companies in the pharmaceutical industry. Notable among these are UCB Biopharma and Sanofi. Her experience in these organizations has contributed to her expertise and innovative capabilities in the field.

Collaborations

Rebecca has collaborated with esteemed colleagues, including James Philip O'Connell and John Robert Porter. These partnerships have likely enhanced her research and development efforts, leading to impactful advancements in her field.

Conclusion

Rebecca Jayne Wootton's contributions to medical innovation, particularly through her patent on TNF alpha trimers, highlight her role as a leading inventor in the treatment of autoimmune and inflammatory disorders. Her work continues to pave the way for new therapeutic approaches that could significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…